The effect of cholinergic enhancement on brain activation in Parkinson*s disease patients with visual hallucinations using fMRI.

Completed

• Conditions: Parkinson's disease; visual hallucinations; 10028037

• Registration Number: NL-OMON33228
• Lead Sponsor: eurologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

- PD according to UK brain bank criteria
- At least weekly VH
- MMSE>24
- FAB>=12

Exclusion Criteria

- Instable internal or psychiatric disease
- Visual acuity <0,5 (Snellen chart)
- Use of ChE-I

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary outcome: cerebral activation change after administration of<br /><br>rivastigmine, compared to placebo, using fMRI</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcomes: Clinical effect of rivastigmine on cognition and extent of<br /><br>VH. Correlation between clinical effect and cerebral activation effect of<br /><br>rivastigmine. </p><br>